http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-2.xsd
Ionizing Radiation and the Immune Response - Part B
This volume, part of the International Review of Cell and Molecular Biology series, delves into the intersection of ionizing radiation and the immune response. It explores the dual impact of radiation therapy on immune responses, focusing on radio-induced lymphopenia and the integration of radiotherapy with natural killer (NK) cell-based therapies. The book examines the role of dendritic cells and the effects of targeted radionuclide therapy, alongside the opportunities and challenges of using low-dose radiation to enhance immunotherapy efficacy. It also covers recent advances in targeting suppressor cells within radiotherapy contexts. Edited by Celine Mirjolet and Lorenzo Galluzzi, the book is intended for researchers and professionals in oncology and immunotherapy, providing insights into the latest developments and applications in the field.
Front Cover -- Ionizing Radiation and the Immune Response -- Part B -- Copyright -- Contents -- Contributors -- Dual impact of radiation therapy on tumor-targeting immune responses -- Acknowledgments -- Competing interests -- References -- Chapter One: Radio-induced lymphopenia in the era of anti-cancer immunotherapy -- 1. Introduction -- 2. Radio-induced lymphopenia (RIL) -- 2.1. Clinical definition -- 2.2. Incidence and therapeutic implications of RIL -- 2.3. Prognostic factors for RIL -- 3. Dynamics of RIL -- 3.1. Depletion phase -- 3.2. Remission phase -- 4. RIL in the era of immunotherapies -- 4.1. Lymphopenia as a poor prognostic factor of outcome in combined radiotherapy/immunotherapy treatments -- 4.2. Synergistic mechanisms -- 4.3. Radiotherapy and immunotherapy combination in clinics -- 5. How to implement efficient lymphocyte sparing radiotherapy? -- 6. Conclusion -- Acknowledgments -- References -- Chapter Two: Combining radiotherapy and NK cell-based therapies: The time has come -- 1. Introduction -- 2. Radiation therapy can improve the NK cell-mediated anti-tumor response -- 2.1. NK expansion and activation depending on dose and fractionation